



**PROF DR
DOMINIQUE
VANDIJCK**
Dept. CEO
KERTEZA
Professor
UGent

SMART INVESTMENTS IN HEALTH TECHNOLOGIES

**TRACK 3: DIGITAL TRANSFORMATION
ENABLES HEALTHCARE RE-INTEGRATION
INTO SOCIETY**

15:00 - 15:30



#T5THC



Smart Investments in Health Technologies



Prof. dr. Dominique Vandijck

► What is meant by 'a technology'

Technology is broadly defined to include the drugs, devices, medical and surgical procedures used in health care, as well as measures for prevention and rehabilitation of disease, and the organisational and support systems in which health care is provided



▶ Do we have to invest in healthcare?

Reeves *et al.* *Globalization and Health* 2013, **9**:43
<http://www.globalizationandhealth.com/content/9/1/43>




RESEARCH


Open Access

Does investment in the health sector promote or inhibit economic growth?

Aaron Reeves^{1*}, Sanjay Basu^{2,3}, Martin McKee³, Christopher Meissner⁴ and David Stuckler^{1,3}




▶ $1 + 1 = 3$



► Take home message to policy makers



▶ The conflicting goals of healthcare policy



► Recommended approach

“to optimize the health of the population within the limits of the available resources, and within an ethical framework built on equity and solidarity principles.”

EU Council of Ministers of Health, 2010



Healthcare costs are rising faster than levels of available funding

ageing population

rise in chronic diseases



high-tech advances

patient demand driven by increased
knowledge of options and by
less healthy lifestyles

▶ Were should we invest in?

Most significant direct impact will, of course, be the **savings achieved for society** as they have fewer healthcare costs to bear.

So, we should focus on these technologies that make this happen

► Where should we invest in?

Most significant direct impact will, of course, be the **savings achieved for society** as they have fewer healthcare costs to bear.

So, we should focus on these technologies that make this happen



oncology
cell & gene therapies
vaccination, infection control
prevention & health promotion
electronic health records
digital innovations
knowledge centers
etc.

▶ What does it mean for innovative technologies / medicines

We need to **make available** and **stimulate** innovative technologies/medicines that offer an **added therapeutic/societal benefit** at an **acceptable cost** and **fill unmet medical needs**



Decisions on pricing, reimbursement, recommending usage, ... should be more and more based on **health economic evaluations**




► What is a health technology assessment?

HTA seeks to **inform health policy makers** by using the best scientific evidence on the **medical, social, economic and ethical implications** of investments in health care.

Assessment includes:

1. Synthesising health research findings about the effectiveness of different health interventions
2. Evaluating the economic implications and analysing cost and cost-effectiveness
3. Appraising social and ethical implications of the diffusion and use of health technologies as well as their organisational implications
4. The HTA process helps identify best practices in health care, thereby enhancing safety, improving quality and saving costs.

► The 'fourth hurdle'



▶ Two views on innovation

"these prices are too high"

"the budgets will explode"

"these medicines offer huge benefits on survival and QoL"

"the medical need is very high"



► Pricing – basically two options

Cost price → price justified by costing structure



acceptable mark-up as compensation for the costs of investment in R&D



difficult to assess the true cost of R&D (what about failures?)



wrong incentives (spend a lot on R&D)



added value not sufficiently recognized

Value-based pricing



better added value is recognized by better rewarding



profit margin may not be in reasonable proportion to the cost structure




evidence may not be sufficiently convincing at launch


▶ What is value?

A photograph of three medical professionals in blue scrubs and white lab coats, with stethoscopes around their necks, holding their hands together in a supportive gesture. The image is overlaid with a teal and orange geometric design. The text "the importance, worth, or usefulness of something" is written in a white, italicized font on the left side.

*“the
importance,
worth, or
usefulness of
something”*

- ▶ Value for money







*“How (health) economics
can contribute to more
and better healthcare,
and so... health?”*

► How to assess technologies added value

Since January 2002: obligated submission of a (pharmaco-)economic form





“What are well spent and what are not well spent resources?”



▶ Health economic reflex

No restriction of means vs. restriction of means



use and reimburse
everything



even in case of any growth,
growth is limited

It is important to, within (the restrictions of) the available budget, make **well-balanced decisions** regarding what is possible and what not



▶ Search for efficiency

Healthcare needs to produce health

= only one part of the story

‘Producing’ means being ‘productive’

= healthcare needs to produce health at the most productive OR the most efficient way



optimal spending of resources

equity

► Search for efficiency

If we want to produce as much health as possible, we need to allocate the (scarce) resources, to those interventions / drugs / technologies / programmes / ... that produce the most health per euro invested ...

... so, to the most productive, the most efficient one!

▶ Three steps of evidence

1. Does it work (compared to placebo)? Does it work in an artificial environment? ('clinical study')


= '*efficacy*'

2. Does it work by patients suffering a particular disease and at relevant parameters? ('real life')

= '*effectiveness*'

3. Demonstrate that the resources spent to this intervention, have good value for money

= '*efficiency*'



▶ Health economic evaluation


The comparative analysis of ≥ 2 interventions in terms of both their costs and health consequences

▶ Value for money

New technology vs. current approach

‘Scenario 1’


Dimension 1 ‘Costs’



▶ Value for money

New technology vs. current approach


‘Scenario 2’



► Value for money

New technology vs. current approach

‘Scenario 3’



► Cost-effectiveness analysis

Basic principles:


1. Calculate the difference in **costs** between 'New' and 'Current'
 $(C_N - C_C)$
2. Calculate the difference in **effectiveness** between 'New' and 'Current'
 $(E_N - E_C)$

new technology is more effective compared to current = health gain
measure of health(gain) = QALY

3. Calculate the **incremental cost-effectiveness ratio** (ICER)
 $(C_N - C_C) / (E_N - E_C)$

results showed in 2 dimensions

► Cost-effectiveness plane



The **economic** value of a QALY is $\pm \text{€}40,000$

► In summary

Better healthcare \neq cheaper healthcare

Main objective of (good) healthcare policy

- Not to waste money / resources
- Producing health
- Realising health gain

Healthcare needs to produce health

= only one part of the story

‘Producing’ means being ‘productive’

= healthcare needs to produce health at the most productive OR the most efficient way

► Conclusion

We should not be driven by costs, but by the **value** of how we intervene ...

But, is the value of an intervention not the extent to which we are able to gain health per euro invested?


Misconception policy  focus on costs

Misconception professionals  focus on effectiveness

Do not generalize, but consider (sub)cohorts of patients, so that decision-making will be better nuanced and individualized.

Invest in technologies that have most impact on savings achieved for society

Decision regarding the allocation of resources is (always) a better decision in presence of a **health-economic evaluation**



@VandijckD

Thank you

for your attention & the kind invitation



E: Dominique.Vandijck@UGent.be

M: +32 479 93 28 01

T: @VandijckD

I: dominique_vandijck